Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial Journal Article
| Authors: | Shitara, K.; Lordick, F.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; Chao, J.; Pazo-Cid, R.; Kang, Y. K.; Yang, J.; Moran, D.; Bhattacharya, P.; Arozullah, A.; Park, J. W.; Oh, M.; Ajani, J. A. |
| Article Title: | Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial |
| Journal Title: | Lancet |
| Volume: | 401 |
| Issue: | 10389 |
| ISSN: | 0140-6736 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2023-05-20 |
| Start Page: | 1655 |
| End Page: | 1668 |
| Language: | English |
| DOI: | 10.1016/s0140-6736(23)00620-7 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 37068504 |
| DOI/URL: | |
| Notes: | Erratum issued, see DOI: 10.1016/S0140-6736(23)01481-2 -- Accession Number: 163796380 -- Entry Date: In Process -- Revision Date: 20230525 -- Publication Type: Article -- Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland -- NLM UID: 2985213R. -- Source: Cinahl |
